The role of novel anticoagulants in the management of venous thromboembolic disease.

OPINION STATEMENT: The introduction of oral direct coagulation factor inhibitors is dramatically changing the landscape of anticoagulation delivery in patients experiencing or at risk for a thrombotic event. These novel anticoagulants can be particularly attractive for health care providers, as they deliver therapeutic anticoagulation at a fixed dose, require no routine coagulation monitoring, and have few drug interactions and no food restrictions. Herein, we will review the role of these novel anticoagulants for acute venous thromboembolism treatment, primary and secondary venous thromboembolism prevention, and management during the periprocedural period.